32 completed, 29 recruiting, 26 unknown, 23 active not recruiting. 63 Phase 2, 41 Not applicable, 21 Phase 1, 16 Phase 3, 1 Early Phase 1.
Follow Radiation Dose Hypofractionation: new trials by email Literature Review of Radiation Dose Hypofractionation trials Research Report on Radiation Dose Hypofractionation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma Hypofractionated Radiotherapy, Normofractionated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | Not applicable | Not yet recruiting | Assiut University | 60 | 2026-10-01 | 2026-09-29 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-28 |
| Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer Hypofractionation, carboplatin + paclitaxel (CP) - Locally Advanced Esophageal or GE Junction Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 60 | 2026-04-28 | 2026-06-08 |
| Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma Hypofractionated Radiotherapy - Head and Neck Squamous Cell Carcinoma | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2026-04-01 | 2026-04-02 |
| Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction hypofractionated radiotherapy, conventional fractionated radiotherapy - Breast Cancer, Breast Reconstruction | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 506 | 2026-03-27 | 2026-06-22 |
| Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer Hypofractionated Radiotherapy, Conventional Radiotherapy - Endometrial Cancer, Cervix Cancer | Not applicable | Recruiting | Siriraj Hospital | 120 | 2026-03-11 | 2026-05-19 |
| Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda Hypofractionated Radiation Therapy, Conventional Fractionated Radiotherapy, Cisplatin - Cervical Cancer, Cervix Cancer | Phase 2 | Recruiting | Uganda Cancer Institute | 278 | 2026-03-11 | 2026-03-27 |
| Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma Hypofractionated radiotherapy - Nasopharyngeal Carcinoma (NPC) | Not applicable | Recruiting | The Second Affiliated Hospital of Hainan Medical University | 24 | 2026-02-20 | 2025-01-28 |
| A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy - Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2026-02-01 | 2026-07-06 |
| Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Advanced Refractory Solid Tumors | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Soochow University | 40 | 2025-12-27 | 2026-01-08 |
| Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial Biospecimen Collection, Chemotherapy, Computed Tomography - Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion | Not applicable | Recruiting | Mayo Clinic | 170 | 2025-12-05 | 2026-10-06 |
| A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer Pirfenidone in combination with a PD-1 inhibitor, hypofractionated radiotherapy - Colorectal Cancer (CRC) | Phase 2 | Recruiting | Tao Zhang | 48 | 2025-12-01 | 2026-06-12 |
| Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, PD-1 inhibitor, TS-1 - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 84 | 2025-11-18 | 2026-01-06 |
| Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy - Head and Neck Cancer, Radiotherapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 27 | 2025-10-15 | 2026-03-03 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery Immediate DIEP flap breast reconstruction, Hypofractionated radiotherapy - Breast Cancer, Breast Reconstruction | Enrolling by invitation | Fudan University | 128 | 2025-09-01 | 2026-09-01 | |
| Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer Biopsy of Breast, Biospecimen Collection, Breast Surgery - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 120 | 2025-05-14 | 2026-09-03 |
| Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer Conventional Radiotherapy, Capecitabine, 5-fluorouracil - Locally Recurrent Rectal Cancer | Phase 2 | Recruiting | Fudan University | 221 | 2025-03-10 | 2025-04-15 |
Showing 20 of 133. Sign in to see all of them.
Breast Neoplasms (29) · Prostatic Neoplasms (16) · Carcinoma, Non-Small-Cell Lung (10) · Sarcoma (9) · Lung Neoplasms (6) · Uterine Cervical Neoplasms (5) · Endometrial Neoplasms (4) · Head and Neck Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Breast Carcinoma In Situ (3) · Carcinoma, Intraductal, Noninfiltrating (3) · Glioblastoma (3) · Liposarcoma, Myxoid (3) · Neoplasms (3) · Pancreatic Neoplasms (3)
Mayo Clinic (10) · M.D. Anderson Cancer Center (6) · Fudan University (4) · Maria Sklodowska-Curie National Research Institute of Oncology (4) · University of Utah (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Chinese Academy of Medical Sciences (3) · Jonsson Comprehensive Cancer Center (3) · National Cancer Institute (NCI) (3) · Second Affiliated Hospital of Soochow University (3) · Sunnybrook Health Sciences Centre (3) · University Hospital, Ghent (3) · University of Washington (3) · West China Hospital (3) · Abramson Cancer Center at Penn Medicine (2)
United States (57) · China (29) · Canada (10) · Egypt (4) · Poland (4) · Belgium (3) · India (3) · France (2) · Mexico (2) · South Korea (2) · Spain (2) · Thailand (2) · Australia (1) · Austria (1) · Brazil (1)
Carlos E. Vargas, M.D. (2) · Carlos E. Vargas, MD (2) · Hui Liu, Professor (2) · Jing Zeng (2) · Roman O. Kowalchuk, MD (2) · Zachary Morris, MD, PhD (2) · Adam Gladwish, MD (1) · Alejandro Sanchez (1) · Alexander Chi, MD (1) · Alexandre A Jacinto, MD (1) · Amar Kishan (1) · Andre Lopes Carvalho, Phd (1) · Andreas Schreiber, M.D., Ph.D. (1) · Andrew Loblaw, MD (1)
PMID 30711522, PMID 24560760, PMID 25936815, PMID 26247543, PMID 27514314, PMID 27622157, PMID 27673513, PMID 27879972, PMID 28185875, PMID 28459606, PMID 28581396, PMID 29029833, PMID 29485064, PMID 29485066, PMID 29863979, PMID 30027292, PMID 30352576, PMID 30527084, PMID 31377161, PMID 32540647, PMID 32554615, PMID 32910709, PMID 33428583, PMID 33538338, PMID 33577365, PMID 33831732, PMID 33933925, PMID 33942954, PMID 33992718, PMID 35014537, PMID 35352512, PMID 35435111, PMID 36343656, PMID 36581983, PMID 37224928, PMID 37696281, PMID 37914139, PMID 38483412, PMID 38578640, PMID 38745333, PMID 38802888, PMID 39192597, PMID 40261490, PMID 40314623, PMID 40366003, PMID 40389098, PMID 40398957, PMID 41405883, PMID 41794436, PMID 42194972
U10CA180868 (2), 2015 (1), 2016 (1), 2017 (1), D43TW009759 (1), P30CA015083 (1), P30CA015704 (1), P30CA042014 (1), P30CA138292 (1), R01CA262388 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186691 (1), UM1CA186716 (1)